LENSAR Laser System Receives 510(k) Clearance for Corneal Pockets, Flaps

April 13, 2018: By Jon Swedien

LENSAR logoLENSAR’s Laser System with Streamline IV has received US FDA 510(k) clearance to perform corneal pockets and flaps for corneal inlay procedures, the Orlando, Florida, company announced April 11.

The system’s new features include a curved-contact patient-interface device that allows surgeons to create the corneal pockets and flaps, LENSAR said.

The company said the device’s new capabilities will be rolled out to US users in 2018.

LENSAR has applied for regulatory approval in the EU and anticipates the new features will be available there in 2018, as well, pending approval, the company said.

The system also features LENSAR’s proprietary augmented reality 3-D model and allows for individual treatment plans, including precise laser delivery and efficient lens fragmentation that can reduce or eliminate the ultrasonic energy delivered into the eye, the company said.

It is the system’s fourth upgrade in two years, LENSAR said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ivantis Gains US FDA Approval for Hydrus Microstent

US FDA Approves Sun Pharma’s CEQUA for Dry Eye

Regeneron Receives US FDA Approval for 12-Week Eylea Dosing

STAAR, Japan’s Shinjuku LASIK Clinic Sign Multiyear Agreement

Alcon Launches Finesse Sharkskin ILM Forceps

Imprimis’ Q2-2018 Revenues Increase 51 Percent to $10.4 Million

Bausch Health Revenues in Q2-2018 Drop 5 Percent

TearLab’s Q2-2018 Revenues Drop 8.5 Percent to $6.4 Million

DeepMind AI System Accurately Detects Eye Disease in OCT Scans at Moorfields

Study by MIT, Mass Eye and Ear Suggests Glaucoma is Autoimmune Disease

Study Indicates Insulin May Restore Vision in Glaucoma

CHOP Researchers Define Six ROP Indicators

Nicox Initiates Phase II Study of NCX 470 in Open-Angle Glaucoma, Ocular Hypertension

Eyenovia’s Microdose Latanoprost Delivers Drug with Precision, Lowers IOP in Proof-of-Concept Study

Rayner to Launch Sulcoflex Trifocal Toric IOL in September

CMS Allows Medicare Advantage Plans to Apply Step Therapy to Retinal Injections

Glaukos Reports Drug Collaboration with D. Western, Q2-2018 Net Sales Increase of 5 Percent

Allergan Will Co-develop Editas’ CRISPR Genome Editing Candidate for LCA10

Spark Reports Q2-2018 Net Sales of $4.3 Million for Luxturna

Aerie’s Rhopressa Posts $2.4 Million in Net Revenues in Q2-2018

Coming soon

2018 Ophthalmic Laser Report: A Global Market Analysis for 2017 to 2023 (Photocoagulation, Photodisruption, and SLT